Search research articles
Contact Us
Filters
Showing results (311-320 of 419) with videos related to
Page
of 42
Sort By:
Journal for Immunotherapy of Cancer
|
July 26, 2024
Treatment-free survival and partitioned survival analysis of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib: 5-year update of CheckMate 214
Charlene M Mantia, Opeyemi A Jegede, Elizabeth R Plimack, et al.
Cancer
|
April 6, 2019
A phase 2, randomized trial evaluating the combination of dalantercept plus axitinib in patients with advanced clear cell renal cell carcinoma
Martin H Voss, Rupal S Bhatt, Nicholas J Vogelzang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 17, 2022
Phase II Trial of Cabozantinib Plus Nivolumab in Patients With Non-Clear-Cell Renal Cell Carcinoma and Genomic Correlates
Chung-Han Lee, Martin H Voss, Maria Isabel Carlo, et al.
Lancet (London, England)
|
June 8, 2023
Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial
Sumanta Kumar Pal, Laurence Albiges, Piotr Tomczak, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
March 15, 2020
First-in-Humans Trial of Dasatinib-Derivative Tracer for Tumor Kinase-Targeted PET
Simone Krebs, Darren R Veach, Lukas M Carter, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 8, 2016
Phase II Trial and Correlative Genomic Analysis of Everolimus Plus Bevacizumab in Advanced Non-Clear Cell Renal Cell Carcinoma
Martin H Voss, Ana M Molina, Ying-Bei Chen, et al.
European Urology Oncology
|
March 30, 2025
A Phase 1b/2 Study of Talazoparib and Axitinib in Patients with Advanced Clear-cell Renal Cell Carcinoma
Ritesh R Kotecha, Sahil D Doshi, Andrea Knezevic, et al.
Cell Metabolism
|
July 6, 2023
Immunometabolic coevolution defines unique microenvironmental niches in ccRCC
Cerise Tang, Amy X Xie, Eric Minwei Liu, et al.
JCO Precision Oncology
|
July 7, 2022
Matched Molecular Profiling of Cell-Free DNA and Tumor Tissue in Patients With Advanced Clear Cell Renal Cell Carcinoma
Ritesh R Kotecha, Erika Gedvilaite, Ryan Ptashkin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 9, 2022
Deciphering radiological stable disease to immune checkpoint inhibitors
J Luo, S Wu, H Rizvi, et al.
Page
of 42
Search research articles
Search
Showing results (311-320 of 419) with videos related to
Sort By:
Page
of 42
Journal for Immunotherapy of Cancer
|
July 26, 2024
Treatment-free survival and partitioned survival analysis of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib: 5-year update of CheckMate 214
Charlene M Mantia, Opeyemi A Jegede, Elizabeth R Plimack, et al.
Cancer
|
April 6, 2019
A phase 2, randomized trial evaluating the combination of dalantercept plus axitinib in patients with advanced clear cell renal cell carcinoma
Martin H Voss, Rupal S Bhatt, Nicholas J Vogelzang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 17, 2022
Phase II Trial of Cabozantinib Plus Nivolumab in Patients With Non-Clear-Cell Renal Cell Carcinoma and Genomic Correlates
Chung-Han Lee, Martin H Voss, Maria Isabel Carlo, et al.
Lancet (London, England)
|
June 8, 2023
Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial
Sumanta Kumar Pal, Laurence Albiges, Piotr Tomczak, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
March 15, 2020
First-in-Humans Trial of Dasatinib-Derivative Tracer for Tumor Kinase-Targeted PET
Simone Krebs, Darren R Veach, Lukas M Carter, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 8, 2016
Phase II Trial and Correlative Genomic Analysis of Everolimus Plus Bevacizumab in Advanced Non-Clear Cell Renal Cell Carcinoma
Martin H Voss, Ana M Molina, Ying-Bei Chen, et al.
European Urology Oncology
|
March 30, 2025
A Phase 1b/2 Study of Talazoparib and Axitinib in Patients with Advanced Clear-cell Renal Cell Carcinoma
Ritesh R Kotecha, Sahil D Doshi, Andrea Knezevic, et al.
Cell Metabolism
|
July 6, 2023
Immunometabolic coevolution defines unique microenvironmental niches in ccRCC
Cerise Tang, Amy X Xie, Eric Minwei Liu, et al.
JCO Precision Oncology
|
July 7, 2022
Matched Molecular Profiling of Cell-Free DNA and Tumor Tissue in Patients With Advanced Clear Cell Renal Cell Carcinoma
Ritesh R Kotecha, Erika Gedvilaite, Ryan Ptashkin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 9, 2022
Deciphering radiological stable disease to immune checkpoint inhibitors
J Luo, S Wu, H Rizvi, et al.
Page
of 42